

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)							
Regd office: 299, THAMBU CHETTY STREET, CHENNAI- 600 001							
Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Period Ended 31st December 2015							
PART I				Rs. In Lakhs			
Particulars	STANDALONE						
	3 months ended (31-12-2015)	3 months ended (30-09-2015)	3 months ended (30-06-2015)	Corresponding 3 months ended in the previous year (31-12-2014)	Year to Date figures for current Period ended (31-12-2015)	Year to Date figures for the previous year ended (31-12-2014)	Previous Year Ended (31-03-2015)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income form Operations							
(a) Net Sales/Income from Operations (net of excise duty)	1,993.22	1,598.82	2,311.98	2,361.50	5,904.02	8,203.54	10,140.94
(b) Other Operating Income		-	-	-	-	4,176.54	4,111.07
Total income from operations (net)	1,993.22	1,598.82	2,311.98	2,361.50	5,904.02	12,380.09	14,252.02
2. Expenditure							
a. Cost of materials consumed	903.33	882.43	415.43	758.60	2,201.19	2,670.41	3,382.64
b. Purchase of stock-in-trade	633.55	473.17	1,431.13	571.64	2,537.85	2,361.89	4,785.89
c. Changes in inventories of finished goods, WIP and stock-in-trade	(0.80)	(214.79)	33.19	741.73	(182.40)	857.57	1,235.84
d. Employees benefits expense	155.38	165.55	159.35	213.51	480.29	843.08	1,034.29
e. Depreciation and amortisation expense	79.01	53.24	102.44	124.29	234.70	487.60	523.76
f. Other expenditure (Any item exceeding 10% of the total expenses relating to continuing operations)	112.63	152.27	71.61	160.88	336.51	766.69	1,278.77
Total Expenses	1,883.11	1,511.88	2,213.16	2,570.65	5,608.15	7,987.25	12,241.20
3. Profit/(Loss) from Operations before Other Income, finance cost and Exceptional Items (1-2)	110.11	86.94	98.82	(209.15)	295.87	4,392.84	2,010.82
4. Other Income	21.55	72.80	27.22	(1.42)	121.57	72.95	113.51
5. Profit/(Loss) from ordinary activities before finance cost and Exceptional Items (3+/- 4)	131.66	159.74	126.04	(210.58)	417.44	4,465.78	2,124.33
6. Finance Costs	289.66	376.67	237.87	240.67	904.20	978.71	1,247.63
7. Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5+/- 6)	(158.00)	(216.93)	(111.83)	(451.24)	(486.76)	3,487.08	876.71
8. Exceptional items	-	-	-	(0.00)	-	268.81	268.81
9. Profit / Loss from Ordinary Activities before tax (7+/- 8)	(158.00)	(216.93)	(111.83)	(451.24)	(486.76)	3,218.27	607.90
10. Tax expense	15.66	23.90	7.44	13.73	47.02	330.36	(2.84)
11. Net Profit / Loss from Ordinary Activities after tax (9 +/- 10)	(173.67)	(240.83)	(119.27)	(464.97)	(533.78)	2,887.90	610.73
12. Extraordinary Item (net of tax expense Rs. lacs)							
13. Net Profit/ Loss for the period (11 +/- 12)	(173.67)	(240.83)	(119.27)	(464.97)	(533.78)	2,887.90	610.73
14. Share of profit/ (loss) of associates*							
15. Minority Interest*							
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 +/- 14 +/- 15)*	(173.67)	(240.83)	(119.27)	(464.97)	(533.78)	2,887.90	610.73
17. Paid up equity share capital (Face value of Rs.10/- each)	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year							
19 (i). Earnings Per Share (EPS) (before extraordinary items) (not annualised)							
a) Basic	(0.93)	(1.29)	(0.64)	(2.49)	(2.86)	17.97	3.27
b) Diluted	(0.93)	(1.29)	(0.64)	(2.49)	(2.86)	17.97	3.27
19 (ii). Earning per share (after extraordinary items) (not annualised)							
a) Basic	(0.93)	(1.29)	(0.64)	(2.49)	(2.86)	17.97	3.27
b) Diluted	(0.93)	(1.29)	(0.64)	(2.49)	(2.86)	17.97	3.27



NOTES

- 1 The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 11.02.2016
- 2 Status of Investor Complaints :

Opening balance	Nil
Pending at the beginning of the quarter	Nil
No. of complaints received and disposed off during the quarter	Nil
Complaints pending at the end of the quarter	Nil
- 3 The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- 4 The Limited Review as required under regulation 33 of the SEBI (LODR) Regulations, 2015 has been completed by the statutory Auditors for the Quarter ended 31.12.2015
- 5 The Schedule IV - Part A- Disclosures in Financial Results has become applicable to the Company for the presentation of Financial statement, accordingly the previous year/ period figures have been regrouped / reclassified wherever necessary
- 6 The MD and Manager-Accounts & Finance certificate in respect of the above results in terms of the requirement of schedule IV (Part A- Disclosure in Financial Results) LSEBI (LODR) Regulations, 2015 has been placed before the Board of Directors.
- 7 The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the Third quarter of the Financial year.

For BAFNA PHARMACEUTICALS LIMITED



Place : Chennai
Date : 11.02.2016


BAFNA MAHAVEER CHAND
MANAGING DIRECTOR
DIN 01458211